{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T10:43:47Z","timestamp":1778928227178,"version":"3.51.4"},"reference-count":46,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2011,9,1]],"date-time":"2011-09-01T00:00:00Z","timestamp":1314835200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2011,9]]},"DOI":"10.2515\/therapie\/2011058","type":"journal-article","created":{"date-parts":[[2011,10,26]],"date-time":"2011-10-26T13:55:39Z","timestamp":1319637339000},"page":"445-452","source":"Crossref","is-referenced-by-count":8,"title":["\u00c9tude co\u00fbt-efficacit\u00e9 de l\u2019adaptation bay\u00e9sienne des posologies des aminosides en g\u00e9riatrie"],"prefix":"10.1016","volume":"66","author":[{"given":"C\u00e9cile Burgos","family":"Leon-Djian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurent","family":"Bourguignon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans-Martin","family":"Sp\u00e4th","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pascal","family":"Maire","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.2515\/therapie\/2011058_bb0005","first-page":"597","article-title":"Aminoglycosides-50 years on","volume":"39","author":"Begg","year":"1995","journal-title":"Br J Clin Pharmacol"},{"key":"10.2515\/therapie\/2011058_bb0010","unstructured":"Vidal 2009."},{"key":"10.2515\/therapie\/2011058_bb0015","series-title":"The complete drug reference","author":"Martindale","year":"2009"},{"issue":"5","key":"10.2515\/therapie\/2011058_bb0020","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1365-2710.1987.tb00539.x","article-title":"Clinical pharmacokinetics, toxicity and cost effectiveness analysis of aminoglycosides and aminoglycoside dosing services","volume":"12","author":"Mathews","year":"1987","journal-title":"J Clin Pharm Ther"},{"issue":"4","key":"10.2515\/therapie\/2011058_bb0025","first-page":"207","article-title":"Aminoglycoside toxicity and relation to dose regimen","volume":"13","author":"Barclay","year":"1994","journal-title":"Adverse Drug React Toxicol Rev"},{"issue":"6136","key":"10.2515\/therapie\/2011058_bb0030","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1136\/bmj.2.6136.549","article-title":"Use of antibiotics. Aminoglycosides","volume":"2","author":"Noone","year":"1978","journal-title":"BMJ"},{"issue":"5","key":"10.2515\/therapie\/2011058_bb0035","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1038\/ki.1980.175","article-title":"Aminoglycoside nephrotoxicity","volume":"18","author":"Kaloyanides","year":"1980","journal-title":"Kidney Int"},{"issue":"1","key":"10.2515\/therapie\/2011058_bb0040","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1046\/j.1365-2125.2001.00377.x","article-title":"The therapeutic monitoring of antimicrobial agents","volume":"52","author":"Begg","year":"2001","journal-title":"Br J Clin Pharmacol"},{"issue":"6866","key":"10.2515\/therapie\/2011058_bb0045","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1136\/bmj.305.6866.1421","article-title":"ABC of monitoring drug therapy. Aminoglycoside antibiotics","volume":"305","author":"Aronson","year":"1992","journal-title":"BMJ"},{"key":"10.2515\/therapie\/2011058_bb0050","series-title":"Nephrology Dialysis Transplantation","first-page":"25","article-title":"Acute renal failure of medical type in an elderly population","author":"Baraldi","year":"1998"},{"issue":"5","key":"10.2515\/therapie\/2011058_bb0055","first-page":"163","article-title":"N\u00e9phrotoxicit\u00e9 des m\u00e9dicaments: veille bibliographique janvier-d\u00e9cembre 2003","volume":"25","author":"Karie","year":"2004","journal-title":"N\u00e9phrologie"},{"issue":"7","key":"10.2515\/therapie\/2011058_bb0060","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.annfar.2004.03.014","article-title":"Monitoring of antibiotic treatment of patient with a severe bacterial infection","volume":"23","author":"Aubert","year":"2004","journal-title":"Ann Fr Anesth Reanim"},{"key":"10.2515\/therapie\/2011058_bb0065","series-title":"Bases rationnelles de la mod\u00e9lisation en th\u00e9rapeutique. Theriaka Rem\u00e8des et Rationalit\u00e9s","author":"Bourguignon","year":"2008"},{"issue":"4","key":"10.2515\/therapie\/2011058_bb0070","doi-asserted-by":"crossref","first-page":"331","DOI":"10.2165\/00003088-199937040-00004","article-title":"Pharmacokinetics and therapeutic drug monitoring of gentamicin in the elderly","volume":"37","author":"Triggs","year":"1999","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"10.2515\/therapie\/2011058_bb0075","first-page":"235","article-title":"Functions of the therapeutic drug monitoring (TDM) Group of the French Society of Pharmacology","volume":"56","author":"Marquet","year":"2001","journal-title":"Therapie"},{"key":"10.2515\/therapie\/2011058_bb0080","article-title":"The USC* PACK PC programs for population pharmacokinetic modeling, modeling of large kinetic\/dynamic systems, and adaptive control of drug dosage regimens","volume":"922\u20134","author":"Jelliffe","year":"1991","journal-title":"Proc Annu Symp Comput Appl Med Care"},{"key":"10.2515\/therapie\/2011058_bb0085","series-title":"M\u00e9thodes d\u2019\u00e9valuation \u00e9conomique des programmes de sant\u00e9","author":"Drummond","year":"1998"},{"issue":"3","key":"10.2515\/therapie\/2011058_bb0090","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1177\/0272989X9001000308","article-title":"The CE, plane: a graphic representation of cost-effectiveness","volume":"10","author":"Black","year":"1990","journal-title":"Medical Decision Making"},{"key":"10.2515\/therapie\/2011058_bb0095","first-page":"655","article-title":"Interest in therapeutic drug monitoring of the main antibiotics","volume":"60","author":"Davani","year":"2002","journal-title":"Ann Biol Clin (Paris)"},{"issue":"2","key":"10.2515\/therapie\/2011058_bb0100","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/j.1365-2125.1989.tb05405.x","article-title":"Individualised aminoglycoside dosage based on pharmacokinetic analysis is superior to dosage based on physician intuition at achieving target plasma drug concentrations","volume":"28","author":"Begg","year":"1989","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"10.2515\/therapie\/2011058_bb0105","first-page":"164","article-title":"Gentamicin dosage requirements: wide interpatient variations in 242 surgery patients with normal renal function","volume":"87","author":"Zaske","year":"1980","journal-title":"Surgery"},{"issue":"1","key":"10.2515\/therapie\/2011058_bb0110","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2165\/00003088-199426010-00006","article-title":"Cost considerations in therapeutic drug monitoring of aminoglycosides","volume":"26","author":"Bertino","year":"1994","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"10.2515\/therapie\/2011058_bb0115","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/00007691-199902000-00010","article-title":"Impact of goal-oriented and model-based clinical pharmacokinetic dosing of aminoglycosides on clinical outcome: A cost-effectiveness analysis","volume":"21","author":"Van Lent-Evers","year":"1999","journal-title":"Ther Drug Monit"},{"issue":"3","key":"10.2515\/therapie\/2011058_bb0120","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.reaurg.2006.03.011","article-title":"Dosage des antibiotiques en r\u00e9animation: quand et comment demander et interpr\u00e9ter les tests?","volume":"15","author":"Potel","year":"2006","journal-title":"R\u00e9animation (Paris 2001)"},{"issue":"6","key":"10.2515\/therapie\/2011058_bb0125","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/clpt.1991.86","article-title":"A controlled trial of the cost benefit of computerized bayesian aminoglycoside administration","volume":"49","author":"Burton","year":"1991","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"10.2515\/therapie\/2011058_bb0130","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1046\/j.1365-2710.2000.00293.x","article-title":"Aminoglycoside usage and monitoring in a Saudi Arabian teaching hospital: a ten-year laboratory audit","volume":"25","author":"Adjepon-Yamoah","year":"2000","journal-title":"J Clin Pharm Ther"},{"key":"10.2515\/therapie\/2011058_bb0135","series-title":"Guide de Th\u00e9rapeutique","author":"Perlemuter","year":"2007"},{"key":"10.2515\/therapie\/2011058_bb0140","series-title":"Pharmacie clinique et th\u00e9rapeutique","author":"Calop","year":"2008"},{"key":"10.2515\/therapie\/2011058_bb0145","series-title":"Mise au point sur le bon usage des aminosides administr\u00e9s par voie injectable","author":"Afssaps","year":"2011"},{"issue":"4","key":"10.2515\/therapie\/2011058_bb0150","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1592\/phco.21.5.443.34490","article-title":"Individualized pharmacokinetic monitoring results in less aminoglycoside-associated nephrotoxicity and fewer associated costs","volume":"21","author":"Streetman","year":"2001","journal-title":"Pharmacotherapy"},{"issue":"4","key":"10.2515\/therapie\/2011058_bb0155","doi-asserted-by":"crossref","first-page":"385","DOI":"10.2165\/00019053-199814040-00005","article-title":"Economic impact of aminoglycoside toxicity and its prevention through therapeutic drug monitoring","volume":"14","author":"Slaughter","year":"1998","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"10.2515\/therapie\/2011058_bb0160","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2165\/00019053-199813010-00004","article-title":"Economic aspects of antibacterial adverse effects","volume":"13","author":"Beringer","year":"1998","journal-title":"Pharmacoeconomics"},{"issue":"6","key":"10.2515\/therapie\/2011058_bb0165","doi-asserted-by":"crossref","first-page":"900","DOI":"10.7326\/0003-4819-107-6-900","article-title":"What is the cost of nephrotoxicity associated with aminoglycosides?","volume":"107","author":"Eisenberg","year":"1987","journal-title":"Ann Intern Med"},{"key":"10.2515\/therapie\/2011058_bb0170","article-title":"Efficience du monitorage pharmacocin\u00e9tique des traitements par aminosides et vancomycines en m\u00e9decine et chirurgie adulte","author":"Benoit","year":"2005"},{"key":"10.2515\/therapie\/2011058_bb0175","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD002894.pub2","article-title":"Computerized advice on drug dosage to improve prescribing practice","volume":"3","author":"Durieux","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.2515\/therapie\/2011058_bb0180","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/00007691-200502000-00004","article-title":"Cost-effectiveness of therapeutic drug monitoring: a systematic review","volume":"27","author":"Touw","year":"2005","journal-title":"Ther Drug Monit"},{"issue":"5","key":"10.2515\/therapie\/2011058_bb0185","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1097\/00007691-199009000-00004","article-title":"Does accepting pharmacokinetic recommendations impact hospitalization? A cost-benefit analysis","volume":"12","author":"Destache","year":"1990","journal-title":"Ther Drug Monit"},{"issue":"3","key":"10.2515\/therapie\/2011058_bb0190","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1093\/jac\/dkl288","article-title":"Inappropriate prescribing of aminoglycosides: risk factors and impact of an antibiotic control team","volume":"58","author":"Zahar","year":"2006","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"10.2515\/therapie\/2011058_bb0195","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1097\/00007691-199312000-00028","article-title":"Use of therapeutic drug monitoring in pharmacoeconomics","volume":"15","author":"Destache","year":"1993","journal-title":"Ther Drug Monit"},{"issue":"1","key":"10.2515\/therapie\/2011058_bb0200","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1177\/106002808902300106","article-title":"Impact of a clinical pharmacokinetic service on patients treated with aminoglycosides for gram-negative infections","volume":"23","author":"Destache","year":"1989","journal-title":"DICP"},{"key":"10.2515\/therapie\/2011058_bb0205","first-page":"83","article-title":"Cost-effectiveness of therapeutic drug monitoring: an update","volume":"13","author":"Touw","year":"2007","journal-title":"EJHP Science"},{"issue":"12","key":"10.2515\/therapie\/2011058_bb0210","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1097\/00003246-199112000-00007","article-title":"Effect of individualized pharmacokinetic dosing on patient outcome","volume":"19","author":"Whipple","year":"1991","journal-title":"Crit Care Med"},{"issue":"3","key":"10.2515\/therapie\/2011058_bb0215","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1097\/00007691-198709000-00010","article-title":"Positive impact of a therapeutic drug-monitoring program on total aminoglycoside dose and cost of hospitalization","volume":"9","author":"Crist","year":"1987","journal-title":"Ther Drug Monit"},{"issue":"2","key":"10.2515\/therapie\/2011058_bb0220","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1093\/clinchem\/44.2.415","article-title":"Therapeutic drug monitoring in special populations","volume":"44","author":"Walson","year":"1998","journal-title":"Clin Chem"},{"issue":"7","key":"10.2515\/therapie\/2011058_bb0225","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1358\/mf.2004.26.7.863736","article-title":"Therapeutic drug monitoring of nonanticancer drugs in cancer patients","volume":"26","author":"Joerger","year":"2004","journal-title":"Methods Find Exp Clin Pharmacol"},{"issue":"6","key":"10.2515\/therapie\/2011058_bb0230","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1097\/00007691-198911000-00003","article-title":"CromWR. Evaluation of aminoglycoside disposition in patients previously treated with cisplatin","volume":"11","author":"Christensen","year":"1989","journal-title":"Ther Drug Monit"}],"container-title":["Therapies"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595716307922?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595716307922?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,6,26]],"date-time":"2020-06-26T14:44:27Z","timestamp":1593182667000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595716307922"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9]]},"references-count":46,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011,9]]}},"alternative-id":["S0040595716307922"],"URL":"https:\/\/doi.org\/10.2515\/therapie\/2011058","relation":{},"ISSN":["0040-5957"],"issn-type":[{"value":"0040-5957","type":"print"}],"subject":[],"published":{"date-parts":[[2011,9]]}}}